about
Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approachInhibition by tyroserleutide (YSL) on the invasion and adhesion of the mouse melanoma cell.Review: starch matrices and the glycemic response.Effect of blood protein concentrations on drug-dosing regimes: practical guidance.Discrepancy in CD3-transmembrane peptide activity between in vitro and in vivo T-cell inhibition.Local Delivery of the Toll-Like Receptor 9 Ligand CpG Downregulates Host Immune and Inflammatory Responses, Ameliorating Established Leishmania (Viannia) panamensis Chronic Infection.
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
In vitro bioassay as a predictor of in vivo response
@nl
In vitro bioassay as a predictor of in vivo response.
@ast
In vitro bioassay as a predictor of in vivo response.
@en
type
label
In vitro bioassay as a predictor of in vivo response
@nl
In vitro bioassay as a predictor of in vivo response.
@ast
In vitro bioassay as a predictor of in vivo response.
@en
prefLabel
In vitro bioassay as a predictor of in vivo response
@nl
In vitro bioassay as a predictor of in vivo response.
@ast
In vitro bioassay as a predictor of in vivo response.
@en
P2860
P356
P1476
In vitro bioassay as a predictor of in vivo response.
@en
P2860
P2888
P356
10.1186/1742-4682-2-3
P407
P577
2005-02-07T00:00:00Z
P5875
P6179
1046506096